[HTML][HTML] Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC
F Xie, M Li, X Jing - Advances in Bioscience and Biotechnology, 2023 - scirp.org
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and
its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field …
its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field …
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
X Wu, Y Huang, Q Zhao, L Wang, X Song, Y Li… - EJNMMI research, 2020 - Springer
Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters.
HAO Luoluo, W Lifeng, M ZHANG… - Chinese Journal of …, 2023 - search.ebscohost.com
Background and objective In recent years, immunotherapy represented by programmed cell
death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly …
death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly …
Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters
L Hao, L Wang, M Zhang, J Yan… - Zhongguo fei ai za zhi …, 2023 - europepmc.org
In recent years, immunotherapy represented by programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the …
1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the …
Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics
X Zhao, Y Zhao, J Zhang, Z Zhang, L Liu, X Zhao - EJNMMI research, 2023 - Springer
Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
M Jreige, I Letovanec, K Chaba, S Renaud… - European journal of …, 2019 - Springer
Abstract Purpose Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …
Correlation of 18F-FDG-PET/CT metabolic parameters with PD-L1 tumour proportion score (TPS) in resected non-small cell lung cancer (NSCLC)
D Hughes, S Hunter, D Nonaka, V Goh, A Bille… - Lung …, 2021 - kclpure.kcl.ac.uk
Introduction: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis play a significant
role in the adjuvant and metastatic treatment of non-small cell lung cancer (NSCLC). PD-L1 …
role in the adjuvant and metastatic treatment of non-small cell lung cancer (NSCLC). PD-L1 …
The value of 18F-FDG PET/CT in predicting the response to PD-1 blocking immunotherapy in advanced NSCLC patients with high-level PD-L1 expression
K Vekens, H Everaert, B Neyns, B Ilsen, L Decoster - Clinical lung cancer, 2021 - Elsevier
Background The objective of this study was to evaluate if 18 F-fluorodeoxyglucose positron
emission tomography/computed tomography (18 F-FDG PET/CT)-derived parameters are …
emission tomography/computed tomography (18 F-FDG PET/CT)-derived parameters are …
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography …
DJ Hughes, E Josephides, R O'Shea… - European …, 2024 - Springer
Background Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer
T Norikane, M Ishimura, K Mitamura… - Journal of Clinical …, 2024 - mdpi.com
Background: Identifying programmed death-ligand-1 (PD-L1) expression is crucial for
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …